The COX-2 inhibitor market withdrawals and prescribing patterns by rheumatologists in patients with gastrointestinal and cardiovascular risk

Clinical and Experimental Rheumatology

Volumn 27, Issue 3, 2009, Pages 395-401

  Greenberg, Jeffrey D ^a   Fisher, Mark C ^a   Kremer, Joel ^b   Chang, Hong ^c   Rosenstein, Elliot D ^d   Kishimoto, Mitsumasa ^e   Lee, Susan ^f   Yazici, Yusuf ^a   Kavanaugh, Arthur ^f   Abramson, Steven B ^a  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e KAMEDA MEDICAL CENTER   (Japan)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cardiovascular; Gastroprotection; NSAID; Utilization

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; MELOXICAM; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PREDNISONE; ROFECOXIB; VALDECOXIB; WARFARIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; DRUG MECHANISM; DRUG UTILIZATION; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; RISK FACTOR; STOMACH PROTECTION; UNITED STATES;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; COHORT STUDIES; CYCLOOXYGENASE 2 INHIBITORS; DRUG UTILIZATION; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REGISTRIES; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 67651177870     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. GABRIEL SE, JAAKKIMAINEN L, BOMBARDIER C: Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991; 115: 787-796
2. HERNANDEZ-DIAZ S, RODRIGUEZ LA: Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000; 160: 2093-2099
3. WOLFE MM, LICHTENSTEIN DR, SINGH G: Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340: 1888-1899 (Pubitemid 29272670)
4. BOMBARDIER C, LAINE L, REICIN A et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-1528
5. HOOPER L, BROWN TJ, ELLIOTT R et al.: The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ 2004; 329: 948.
6. DAI C, STAFFORD RS, ALEXANDER GC: National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation. Arch Intern Med 2005; 165: 171-177
7. GREENBERG JD, BINGHAM CO, 3RD, ABRAMSON SB et al.: Assessment of coxib utilization by rheumatologists for nonsteroidal antiinflammatory drug gastroprotection prior to the coxib market withdrawals. Arthritis Rheum 2006; 55: 543-550
8. http://www.fda.gov/bbs/topics/news/2005/NEW01171.html 4/7/2005.
9. http://www.vioxx.com/vioxx/documents/english/vioxx-press-release.pdf 9/30/2004.
10. KREMER J: The CORRONA database. Ann Rheum Dis 2005; 64 (Suppl. 4): iv37-41.
11. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000; 43: 1905-1915
12. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002; 46: 328-346
13. SAAG KG, OLIVIERI JJ, PATINO F et al.: Measuring quality in arthritis care: the Arthritis Foundation's quality indicator set for analgesics. Arthritis Rheum 2004; 51: 337-349 (Pubitemid 38725131)
14. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421
15. SMALLEY W, STEIN CM, ARBOGAST PG et al.: Underutilization of gastroprotective measures in patients receiving nonsteroidal antiinflammatory drugs. Arthritis Rheum 2002; 46: 2195-2200
16. STURKENBOOM MC, BURKE TA, DIELEMAN JP et al.: Underutilization of preventive strategies in patients receiving NSAIDs. Rheumatology (Oxford) 2003; 42 (Suppl. 3): iii23-31.
17. SUN SX, LEE KY, BERTRAM CT et al.: Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization. Curr Med Res Opin 2007; 23: 1859-1866
18. SINGH G, VADHAVKAR S, MITHAL A et al.: A new safety warning: decreased gastroprotection is associated with an increase of serious ulcer complications in elderly users of NSAIDs. Arthritis Rheum 2007; 56: S287.
19. RAY WA, STEIN CM, DAUGHERTY JR et al.: COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002; 360: 1071-1073
20. REICIN AS, SHAPIRO D, SPERLING RS et al.: Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). Am J Cardiol 2002; 8: 204-209
21. SOLOMON DH, SCHNEEWEISS S, GLYNN RJ et al.: Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004; 109: 2068-2073
22. FARKOUH ME, KIRSHNER H, HARRINGTON RA et al.: Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004; 364: 675-684 (Pubitemid 39140623)
23. GRAHAM DJ, CAMPEN D, HUI R et al.: Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclooxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005; 365: 475-481
24. LEVESQUE LE, BROPHY JM, ZHANG B: The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 2005; 142: 481-489 (Pubitemid 40490913)
25. SILVERSTEIN FE, FAICH G, GOLDSTEIN JL et al.: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-1255
26. SOLOMON DH, GLYNN RJ, LEVIN R et al.: Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med 2002; 162: 1099-1104 (Pubitemid 34522394)
27. CATELLA-LAWSON F, REILLY MP, KAPOOR SC et al.: Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809-1817 (Pubitemid 34940862)
28. MACDONALD TM, WEI L: Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003; 361: 573-574
29. CAPONE ML, SCIULLI MG, TACCONELLI S et al.: Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 2005; 4: 1295-1301 (Pubitemid 40523153)
30. VAN RYN J, KINK-EIBAND M, KURITSCH I et al.: Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers. J Clin Pharmacol 2004; 44: 777-784
31. FISCHER LM, SCHLIENGER RG, MATTER CM et al.: Current use of nonsteroidal antiinflammatory drugs and the risk of acute myocardial infarction. Pharmacotherapy 2005; 25: 503-510
32. GARCIA RODRIGUEZ LA, VARAS-LORENZO C, MAGUIRE A et al.: Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation 2004; 109: 3000-3006
33. KURTH T, GLYNN RJ, WALKER AM et al.: Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 2003; 108: 1191-1195
34. SCHLIENGER RG, JICK H, MEIER CR: Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction. Br J Clin Pharmacol 2002; 54: 327-332 (Pubitemid 35056578)